OBJECTIVE: To determine whether cytochrome P450 (CYP)2C19 haplotype associates with lansoprazole-associated adverse event frequency. STUDY DESIGN:Respiratory adverse events from a clinical trial of lansoprazole in children with asthma were analyzed for associations with extensive or poor metabolizer (PM) phenotype based on CYP2C19 haplotypes. Carriers of CYP2C19*2, *3, *8, or *9 alleles were PMs; carriers of 2 wild-type alleles were extensive metabolizers (EMs). Plasma concentrations of lansoprazole were determined in PM and EM phenotypes. RESULTS: The frequency of upper respiratory infection among PMs (n = 45) was higher than that among EMs (n = 91), which in turn was higher than that in placebosubjects (n = 135; P = .0039). The frequency of sore throat (ST) was similarly distributed among EMs and PMs (P = .0015). The OR (95% CI) for upper respiratory infections in PMs was 2.46 (1.02-5.96) (P = .046); for EMs, the OR (95% CI) was 1.55 (0.86-2.79). The OR (95% CI) for ST in EMs and PMs was 2.94 (1.23-7.05, P = .016) vs 1.97 (1.09-3.55, P = .024), respectively. Mean ± SD plasma concentrations of lansoprazole were higher in PMs than in EMs: 207 ± 179 ng/mL vs 132 ± 141 ng/mL (P = .04). CONCLUSIONS:Lansoprazole-associated upper respiratory infections and ST in children are related in part to CYP2C19 haplotype. Our data suggest that lansoprazole-associated adverse events in children may be mitigated by adjusting the conventional dose in PMs. Additional studies are required to replicate our findings.
RCT Entities:
OBJECTIVE: To determine whether cytochrome P450 (CYP)2C19 haplotype associates with lansoprazole-associated adverse event frequency. STUDY DESIGN: Respiratory adverse events from a clinical trial of lansoprazole in children with asthma were analyzed for associations with extensive or poor metabolizer (PM) phenotype based on CYP2C19 haplotypes. Carriers of CYP2C19*2, *3, *8, or *9 alleles were PMs; carriers of 2 wild-type alleles were extensive metabolizers (EMs). Plasma concentrations of lansoprazole were determined in PM and EM phenotypes. RESULTS: The frequency of upper respiratory infection among PMs (n = 45) was higher than that among EMs (n = 91), which in turn was higher than that in placebo subjects (n = 135; P = .0039). The frequency of sore throat (ST) was similarly distributed among EMs and PMs (P = .0015). The OR (95% CI) for upper respiratory infections in PMs was 2.46 (1.02-5.96) (P = .046); for EMs, the OR (95% CI) was 1.55 (0.86-2.79). The OR (95% CI) for ST in EMs and PMs was 2.94 (1.23-7.05, P = .016) vs 1.97 (1.09-3.55, P = .024), respectively. Mean ± SD plasma concentrations of lansoprazole were higher in PMs than in EMs: 207 ± 179 ng/mL vs 132 ± 141 ng/mL (P = .04). CONCLUSIONS:Lansoprazole-associated upper respiratory infections and ST in children are related in part to CYP2C19 haplotype. Our data suggest that lansoprazole-associated adverse events in children may be mitigated by adjusting the conventional dose in PMs. Additional studies are required to replicate our findings.
Authors: J J Lima; S Mohapatra; H Feng; R Lockey; P K Jena; M Castro; C Irvin; J A Johnson; J Wang; J E Sylvester Journal: Clin Exp Allergy Date: 2008-02-20 Impact factor: 5.018
Authors: Jason E Lang; Janet T Holbrook; Edward B Mougey; Christine Y Wei; Robert A Wise; W Gerald Teague; John J Lima Journal: Ann Am Thorac Soc Date: 2015-06
Authors: James P Franciosi; Edward B Mougey; Andre Williams; Roberto A Gomez Suarez; Cameron Thomas; Christa L Creech; Katherine George; Diana Corao; John J Lima Journal: Eur J Pediatr Date: 2017-12-06 Impact factor: 3.183
Authors: Christiana J Bernal; Ida Aka; Robert J Carroll; Joseph R Coco; John J Lima; Sari A Acra; Dan M Roden; Sara L Van Driest Journal: Pediatrics Date: 2019-11-07 Impact factor: 7.124
Authors: Monica Tang; Robert J Henderson; Janet T Holbrook; Loretta G Que; Anne M Mathews; Robert A Wise; Anne E Dixon; Stephen P Peters; Linda Rogers; Lewis J Smith; W Gerald Teague; Jason E Lang Journal: J Allergy Clin Immunol Pract Date: 2018-10-09
Authors: Keith Feldman; Gregory L Kearns; Robin E Pearce; Susan M Abdel-Rahman; James Steven Leeder; Alec Friesen; Vincent S Staggs; Andrea Gaedigk; Jaylene Weigel; Valentina Shakhnovich Journal: Clin Transl Sci Date: 2022-02-14 Impact factor: 4.438
Authors: John J Lima; Cameron D Thomas; Julia Barbarino; Zeruesenay Desta; Sara L Van Driest; Nihal El Rouby; Julie A Johnson; Larisa H Cavallari; Valentina Shakhnovich; David L Thacker; Stuart A Scott; Matthias Schwab; Chakradhara Rao S Uppugunduri; Christine M Formea; James P Franciosi; Katrin Sangkuhl; Andrea Gaedigk; Teri E Klein; Roseann S Gammal; Takahisa Furuta Journal: Clin Pharmacol Ther Date: 2020-09-20 Impact factor: 6.903